A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features

Enrolling by invitationOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

April 24, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions

PsoriasisEczemaJAK Inhibitor

Interventions

DRUG

Deucravacitinib 6mg po qd

oral administration

Trial Locations (1)

Shanghai general hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors

lead

Xi Tan

OTHER